A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, INTEGRATED SINGLE ASCENDING DOSE, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 691 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH MILD-TO-MODERATE ASTHMA

Intervention/treatment:
AMG 691
Medical condition:
ASTHMA
Protocol code:
20230151
Control number:
296003
Status:
Active, not recruiting
Approved:
April 11, 2025
Trial phase:
Phase 1
For more information:
ClinicalTrials.gov - NCT06637371
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 70 Years
Accepts healthy volunteers: Yes

Contacts and locations

Contact
Name
Amgen Call Center
Role
CONTACT
Phone:
866-572-6436
Sponsor
AMGEN CANADA INC

Locations

Ontario

Winchester District Memorial Hospital
Winchester, Ontario, K0C 2K0
RECRUITING
Did you find what you were looking for?